The compound MK-801{(+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine maleate)} is a potent anticonvulsant that is active after oral administration and whose mechanism of action is unknown. We have detected high-affinity (Kd = 37.2 ± 2.7 nM) binding sites for [3HJMK-801 in rat brain membranes. These sites are heat-labile, stereoselective, and regionally specific, with the hippocampus showing the highest density of sites, followed by cerebral cortex, corpus striatum, and medulla-pons. There was no detectable binding in the cerebellum. MK-801 binding sites exhibited a novel pharmacological profile, since none of the major neurotransmitter candidates were active at these sites. 
801 in rat brain membranes. These sites are heat-labile, stereoselective, and regionally specific, with the hippocampus showing the highest density of sites, followed by cerebral cortex, corpus striatum, and medulla-pons. There was no detectable binding in the cerebellum. MK-801 binding sites exhibited a novel pharmacological profile, since none of the major neurotransmitter candidates were active at these sites. The excitatory amino acids L-glutamate and L-aspartate are thought to act as the principal excitatory neurotransmitters in mammalian brain. The receptors mediating their actions are generally divided into the major subtypes N-methyl-D-aspartate (N-Me-D-Asp, sometimes referred to as "NMDA"), quisqualate, and kainate, based on their activation by these selective agonists (1) (2) (3) (4) (5) (6) and have been shown to possess a remarkable ability to protect against permanent neuronal damage in animal models of cerebral ischemia and hypoglycemia (7, 8) . In the present studies we describe a noncompetitive N-Me-D-Asp antagonist known from previous studies to penetrate readily into the central nervous system. The compound is MK-801 {(+)-5- (Fig. 1) , a substance previously reported to possess an unusual spectrum of pharmacological activities as a potent anticonvulsant that exhibits both anxiolytic and sympathomimetic properties (9) (10) (11) .
We used [3H]MK-801 of high specific activity to identify a population of high-affinity binding sites in rat brain.
Neurophysiological experiments showed that MK-801 selectively and noncompetitively antagonized the excitatory actions of N-Me-D-Asp in rat brain.
MATERIALS AND METHODS
[3H]MK-801 (22.3 Ci/mmol; 1 Ci = 37 GBq) was prepared from the 7-bromo analog of MK-801 by tritium-halogen exchange. This precursor, together with samples of MK-801 and its (-) Incubation was terminated by rapid filtration through Whatman GF/B filters, which were washed immediately with two 5-ml portions of ice-cold assay buffer in a Brandel M 24-R cell harvester. The time required for the complete filtration and washing procedure was less than 10 sec. Radioactivity on the filters was determined by liquid scintillation counting in standard vials with 10 ml of Hydrofluor (National Diagnostics, Somerville, NJ) at 41% counting efficiency. Protein concentrations were determined according to the method of Lowry et al. (12) .
For in vitro neurophysiological experiments, cortical slices of rat brain were prepared in a manner similar to that described by Harrison and Simmonds (13 10,047, although these were 30-250 times less potent than MK-801 itself ( Fig. 3 and Results are from single experiments, which were all repeated at least four times (see Table 2 ). (Fig. 4) . The effect of MK-801 was persistent, with only partial recovery after a 3-hr wash-out period. In Mg2 -free aCSF and in the absence of tetrodotoxin, spontaneous paroxysmal depolarizing shifts were present in the majority of slices (13) (Fig. 6) .
DISCUSSION
In the present study, we used biochemical and electrophysiological techniques to identify the mechanism of action of the potent anticonvulsant MK-801 (9 (Table 2 ). However, preliminary While phencyclidine, (±)-ketamine, and (+)-SKF 10,047 have modest affinities for the MK-801 site, they are also known to interact with a-opioid receptors (19) (20) (21) (22) (23) 25 2), the pharmacological specificity of the o site differs in that haloperidol is more potent than SKF 10,047, followed by phencyclidine and ketamine (21, 22) . Furthermore, the oa site, as labeled by tritiated (+)-SKF 10,047 and (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine, occurs in highest density in the brainstem and cerebellum and is present at only low densities in the hippocampus and cortex (19) (20) (21) (22) .
Our results provide an explanation for the mechanism of action of the orally active anticonvulsant MK-801. This compound acts at a functionally distinct site in mammalian brain that is related to the N-Me-D-Asp subtype of excitatory amino acid receptors. These findings have important implications for the potential future use of MK-801 in the treatment of epilepsy and as a protective agent in neurodegenerative disorders (24) .
